Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

While a JAMA study found a decline in mpox antibody responses after vaccination, a University of Oxford expert cautioned that ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

While it isn’t clear what triggered the $82 million payment, the announcement comes a week after AbbVie said that its ...

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

After the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder, companies are ...

ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go ...